PHOX2B CAR T-Cells for Relapsed Neuroblastoma
Contact
Description
The purpose of this study is to test an experimental approach called cell therapy for neuroblastoma. This study will take a patient's own white blood cells (T cells) and change them to turn against the cancer. CART cells have been used to treat other cancers, but PHOX2B CART cells have not been administered to human patients prior to this clinical trial. Participants will be given PHOX2B cells via an IV and then monitored for up to 12 months.
Participants will also be asked to sign consent to a separate long term follow-up protocol to monitor their health for up to 15 years after their last PHOX2B CART treatment.
Eligibility and criteria
What to expect
This study will take place at CHOP's Philadelphia Campus.
Active participation lasts for 12 months. Study visits include Screening/Enrollment, Pre-Infusion, Day-1, Infusion (Day o), Day 1, Day 3, Day 7, Day 10, Day 14, Day 21, Day 28, Week 6, Month 2, Week 10, Month 3, Month 4, Month 5, Month 6, Month 9, and Month 12. Possible procedures include:- medical record review
- chemotherapy
- PHOX2B cell infusion
- blood draws
- physical exams
- imaging
- disease assessments, including bone marrow biopsies
Related specialties
Related conditions
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.